BiotechTube

Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solution

ApprovedRecruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Peritoneal Dialysis

Conditions

Peritoneal Dialysis

Trial Timeline

May 24, 2023 → Dec 31, 2025

NCT ID
NCT05721404

About Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solution

Icodextrin Peritoneal Dialysis Solution + Hypertonic Dextrose solution is a approved stage product being developed by Baxter for Peritoneal Dialysis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05721404. Target conditions include Peritoneal Dialysis.

What happened to similar drugs?

2 of 6 similar drugs in Peritoneal Dialysis were approved

Approved (2) Terminated (1) Active (4)
✅ertapenemMerckApproved
✅Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
🔄R744 + R744Chugai PharmaceuticalPhase 3
🔄roxadustatAstellas PharmaPhase 3
🔄PA21Kissei PharmaceuticalPhase 3
🔄Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05721404ApprovedRecruiting

Competing Products

20 competing products in Peritoneal Dialysis

See all competitors
ProductCompanyStageHype Score
azenosertibZentalis PharmaceuticalsPhase 2
32
MCY-M11 + CyclophosphamideMaxCytePhase 1
11
R744 + R744Chugai PharmaceuticalPhase 3
40
roxadustatAstellas PharmaPhase 3
40
AbemaciclibEli LillyPhase 1
36
M200 (Volociximab) + Liposomal Doxorubicin + M200 (Volociximab) + M200 (Volociximab)AbbViePhase 1/2
32
Adavosertib + Paclitaxel + Carboplatin + Gemcitabine + PLDAstraZenecaPhase 2
35
Tremelimumab + OlaparibAstraZenecaPhase 1
21
ertapenemMerckApproved
43
Octreotide LAR + Octreotide (Immediate release) + methylprednisolone + PlaceboNovartisPhase 2
35
PA21Kissei PharmaceuticalPhase 3
40
PF-06873600 + Endocrine Therapy 1 + Endocrine Therapy 2PfizerPhase 1/2
24
Bevacizumab + Nivolumab + RucaparibBristol Myers SquibbPhase 2
39
IniparibSanofiPhase 2
35
Sevelamer Hydrochloride (Renagel®) + Calcium acetate (PhosLo® )SanofiPhase 3
40
nanoliposomal irinotecanIpsenPhase 1
26
Extraneal (7.5% icodextrin) Peritoneal Dialysis SolutionBaxterApproved
32
Anti-Adhesion ProductBaxterPhase 2
32
PioglitazoneBaxterPre-clinical
23
RadspherinOncoinventPhase 2
32